Misoprostol exposure during first trimester of pregnancy: Doubts about teratogenicity;Cytotec® (misoprostol) au 1er trimestre de la grossesse: Doutes sur un effet malformatif

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 33, Issue 4, 2004, Pages 337-338

  Vauzelle Gardier, C ^a   Assari Merabtene, F ^a   Cournot, M P ^a   Elefant, E ^a  

^a ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MISOPROSTOL;

ARTHROGRYPOSIS; EPIDEMIOLOGICAL DATA; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; LETTER; MOEBIUS SYNDROME; PERINATAL DRUG EXPOSURE; PRESCRIPTION; TERATOGENICITY;

EID: 3042640525     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0368-2315(04)96466-6     Document Type: Letter

References (5)

1. Gonzalez CH, Marques-Dias MJ, Kim CA, Sugayama SMM, Da Paz JA, Huson SM et al. Congenital abnormalities in brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 1998; 351: 1624-7.
2. Pastuszak A, Schuler L, Speck-Martins CE, Coelho KEFA, Cordello SM, Vargas F et al. Use of misoprostol during pregnancy and Möbius' syndrome in infants. N Engl J Med 1998; 338: 1881-5.
3. Schuler L, Pastuszak A, Sanseverino MTV, Orioli IM, Brunoni D, Ashton-Prolla P et al. Pregnancy outcome after exposure to misoprostol in Brazil: a prospective controlled study. Reprod Toxicol 1999; 13: 147-51.
4. Vargas FR, Schuler-Faccini L, Brunoni D, Kim C, Meloni VFA, Sugayama SMM et al. Prenatal exposure to misoprostol and vascular disruption defects: a case-control study. Am J Med Genet 2000; 95: 302-6.
5. Carlier P, Vial T, Robert E, Jean-Pastor MJ. Misoprostol (Cytotec®) exposure during pregnancy: a french collaborative study. Congrès de la Société Française de Pharmacologie, 20e Journées de Pharmacovigilance, Nantes, 1999.